Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/10/2019
SIETES contiene 92826 citas

 
 
 1 a 20 de 44 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med 2019:30 de julio. [Ref.ID 103183]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103067]
3.Enlace a cita original Cita con resumen
Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ 2018;360:6 de febrero. [Ref.ID 102541]
4. Cita con resumen
Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017;376:2300-2. [Ref.ID 101628]
5. Cita con resumen
Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf 2017;26:712-21. [Ref.ID 101627]
6.Tiene citas relacionadas Cita con resumen
7. Cita con resumen
Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf 2015;38:565-75. [Ref.ID 99239]
8. Cita con resumen
Patorno E, Neuman MD, Schneeweiss S, Mogun H, Bateman BT. Comparative safety of anesthetic type for hip fracture surgery in adults: retrospective cohort study. BMJ 2014;349:g4022. [Ref.ID 98063]
9. Cita con resumen
Bateman BT, Bykov K, Choudhry NK, Schneeweiss S, Gagne JJ, Polinski JM, Franklin JM, Doherty M, Fischer MA, Rassen JA. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ 2013;347:13. [Ref.ID 96347]
10. Cita con resumen
Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, Nourjah P, Sauer B, Schumock GT, Sedrakyan A, Sürmer T, West SL, Schneeweiss S. The incidence user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 2013;22:1-6. [Ref.ID 94655]
11. Cita con resumen
Choudhry NK, Fischer MA, Avorn JL, Lee JL, Schneeweiss S, Solomon DH, Berman C, Jan S, Lii J, Mahoney JJ, Shrank WH. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol 2012;60:1817-24. [Ref.ID 93132]
12.Tiene citas relacionadas Cita con resumen
Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012;344:16. [Ref.ID 92610]
13. Cita con resumen
Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, Reisman L, Fernandes J, Spettell C, Lee JL, Levin R, Brennan T, Shrank WH, for the Post-Myocardial Infarction Free RX Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088-97. [Ref.ID 91660]
14. Cita con resumen
Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Shrank WH. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011;171:814-21. [Ref.ID 91371]
15.Tiene citas relacionadas Cita con resumen
Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011;305:2525-31. [Ref.ID 91336]
16. Cita con resumen
Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of comparative efficacy data at the time of drug approval in the United States. JAMA 2011;305:1786-9. [Ref.ID 90775]
17. Cita con resumen
Schneeweiss S, Avorn J. Postmarketing studies of drug safety. BMJ 2011;342:344-5. [Ref.ID 90208]
18.Tiene citas relacionadas
Solomon DH, Rassen JA, Glynn RJ, Garneau K, Levin R, Lee J, Schneeweiss S. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010;170:1979-86. [Ref.ID 89783]
19.Tiene citas relacionadas Cita con resumen
Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010;170:1968-78. [Ref.ID 89781]
20.Tiene citas relacionadas Cita con resumen
Shrank WH, Choudhry NK, Fischer MA, Avorn J, Powell M, Schneeweiss S, Liberman JN, Dollear T, Brennan TA, Brookhart MA. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med 2010;153:633-40. [Ref.ID 89657]
Seleccionar todas
 
 1 a 20 de 44 siguiente >>